CCR8 + Tregs were essential for cardiac protection after myocardial infarction, as their deletion worsened cardiac function and increased inflammation.
Class 2 obesity was associated with a 2.1-fold and class 3 obesity with a 3.0-fold increased risk of heart failure compared to normal weight individuals.
PRMT9 overexpression in macrophages reduced infarct size and improved cardiac function after MI by facilitating STAT1 degradation and suppressing M1-like polarization.
Olezarsen reduced postprandial triglyceride AUC by 55% and decreased intracellular lipid droplets in monocytes by 25.0% in hypertriglyceridemic patients.
In patients with diabetes and multivessel disease undergoing PCI, ticagrelor was not noninferior to prasugrel for the composite primary outcome at 1 year (16.6% vs 14.2%; P = .12).
A standardized framework for evaluating predictive models and biomarkers is essential for improving cardiovascular disease prevention in diverse populations.
A nationwide study assesses mortality risk and treatment effects in heart failure patients with pacemakers, suggesting key interventions.
A randomized clinical trial demonstrates improved sinus rhythm restoration in patients using a handheld device for Valsalva maneuver.
A meta-analysis compares 5-year outcomes of TAVI and SAVR in low- to intermediate-risk patients, indicating SAVR may be superior.
SGLT2i initiation within 6 weeks post-HF hospitalization reduced 1-year all-cause mortality by 25% (HR 0.75) compared to non-users in patients with newly diagnosed HFrEF.